Goserein (Zoladex) in premenopausal advanced breast cancer: duration of response and survival

A.R. Dixon1, J.F.R. Robertson1, L. Jackson1, R.I. Nicholson2, K.J. Walker2 & R.W. Blamey1

1Department of Surgery, City Hospital, Hucknall Road, Nottingham NG5 6JE; and 2Tenovus Institute for Cancer Research, University of Wales College of Medicine, Cardiff CF4 4XX, UK.

Summary In premenopausal women with advanced breast cancer the luteinising hormone-releasing hormone agonist goserein (Zoladex, ICI plc) will produce serum levels of oestradiol equivalent to those following surgical oophorectomy or the menopause. This paper reports our further experience of using this drug in 75 premenopausal patients with advanced breast cancer. In addition to response rates, duration of response is reported. An objective response was seen in 22 patients (33%), the median duration of which was in excess of 15 months. Seven patients (9%) showed a complete response to therapy; median duration >37 months. There was no significant difference in time to disease progression (Lee-Desu statistic 18.26, 1 d.f., \( P = 0.43 \)) and probability of survival (Lee-Desu statistic 3.41, 1 d.f., \( P = 0.07 \)) between those patients assessed as having either either static disease, or those showing a partial response at six months. Response to therapy correlates significantly with the oestrogen receptor status of the primary tumour (\( \chi^2 = 20.59, 6 \text{ d.f.}, \ P < 0.005 \)). The modest side-effects, ease of administration and reversibility make this approach to therapy very attractive. This is to be remembered in that 53% of patients had disease progression whilst receiving goserein. These patients thus avoided the unnecessary and irreversible morbidity associated with surgical oophorectomy. With the proven efficacy and minimal morbidity associated with goserein we believe there is no current role for surgical oophorectomy in the management of premenopausal patients with advanced breast cancer.

Table I Sites of disease in 75 patients receiving monthly, depot, subcutaneous goserein

| No. of patients |
|-----------------|
| Locally advanced primary | 15 |
| Locoregional recurrence | 6 |
| Locoregional recurrence with metastases | 16 |
| Metastatic disease | 38 |

The endocrine effects and clinical efficacy of the luteinising hormone-releasing hormone (LH-RH) agonist goserein (Zoladex, ICI plc) as initial hormone therapy for premenopausal advanced breast cancer patients have been previously reported (Nicholson et al., 1984, 1985; Williams et al., 1986; Walker et al., 1986). In a study of 53 premenopausal patients we reported a response rate to goserein of 31%; comparable to our previous experience of surgical oophorectomy (Williams et al., 1986; Buchanan et al., 1986). Recently we have described our experience of combining goserein with the anti-oestrogen tamoxifen (Robertson et al., 1989a; Walker et al., 1989). Slightly lower levels of serum oestradiol were recorded in those patients receiving combination therapy, along with significant reductions in LH and FSH as compared with goserein alone. An international multicentre trial is currently underway to determine any clinical advantage of such a combination.

The current paper updates our experience of treating 75 premenopausal advanced breast cancer patients with monthly depot injections of goserein 3.6 mg; particular address has been given to both the duration of response and survival probability.

Patients and methods

Seventy-five premenopausal patients with histologically proven advanced breast cancer have been treated by the administration of the gonadotrophin releasing hormone agonist goserein, subcutaneous implantation of a 3.6 mg depot preparation at 28 day intervals. No patient had received previous endocrine or cytotoxic therapies; all gave written informed consent to the administration of the drug. The median age of the patients on commencing therapy was 44 years (range 31–55), with the sites of disease as shown in Table I. The major sites of metastatic disease in 54 patients were: bone, 22 patients; pulmonary, 14 patients; bone and pulmonary, 12 patients; visceral, six patients.

Initial examination included a full clinical examination with documentation of all measurable disease and photography where appropriate. A limited skeletal survey was obtained in all patients. CT scans, isotope bone scans and liver sonography were performed when clinically indicated. Routine haematological and biochemical estimations were also performed. Tumour steroid hormone receptor status was known in 60 patients; the oestrogen receptor assays having been performed by the Tenovus Institute, Cardiff using the commercially available ER-enzyme immunoassay (Abbot ER-Eia, monoclonal). Oestrogen receptor was considered positive when a value greater than 5 fmol mg\(^{-1}\) cytosol protein was obtained (Nicholson et al., 1981).

Patients were assessed for response according to UICC criteria (Hayward et al., 1977). The British Breast Group recommendation that the minimum duration of remission be six months was also adhered to (British Breast Group, 1974).

Statistical methods

Actuarial survival analysis was performed using the statistical package SPSSX-21 (SPSS, 1986) life table analysis which calculates Gehan's generalised Wilcoxon rank test for censored data (Lee & Desu, 1972).

Results

Twenty-five of the 75 patients (33%) in whom disease was assessable using the strict clinical criteria of the UICC (Hayward et al., 1977) and the BBG (British Breast Group, 1974) were classified as having shown an objective response to therapy of at least 6 months duration. A complete response (CR) was seen in seven patients (9%), the median duration of which was in excess of 37 months. Three of these responders had stage III disease, while four had locoregional recurrence; three of whom also had metastases (two pulmonary, one bone). Static disease (SD) was seen in a further 11 patients (15%), whilst the remaining 39 patients (52%) progressed (PD) within 6 months of goserein. Duration of response is recorded in Table II. The probability of
disease progression in response to therapy is summarised in Figure 1. There is no significant difference in the time to disease progression between those patients assessed as having shown a partial response (PR) to goserelin at 6 months, and those that have stable disease (Lee-Desu statistic 0.63, 1 d.f., P = 0.43); survival does not significantly differ between these two groups (Lee-Desu statistic 3.41, 1 d.f., P = 0.07). Patients showing a complete response had a significantly increased time interval to disease progression as compared to those that showed a partial response (Lee-Desu statistic 6.69, 1 d.f., P = 0.009). The side-effects of goserelin included amenorrhoea, hot flushes, vaginal dryness, and occasional nausea.

Primary tumour oestrogen receptor (ER) status was available in 60 patients (80%); 32 patients were ER positive, and 28 ER negative (see Table III). Nineteen of the 24 patients responding to goserelin were ER positive, while three had unknown receptor status. Of the seven patients that showed a complete response, six had ER positive primary tumours. Twenty-eight patients with tumours that were ER negative; 21 of these had progressive disease. The oestrogen receptor status of the primary tumour correlates significantly with the prediction of response to goserelin (χ² = 20.59, 6 d.f., P < 0.005).

Discussion

Surgical oophorectomy has become the mainstay of treatment for premenopausal patients with advanced breast cancer since it was first introduced by Beatson at the end of the last century (Beatson, 1896). This surgical approach suffers many disadvantages in that treatment is palliative and the majority of patients will not respond, thus exposing many to unnecessary and irreversible morbidity (Kennedy et al., 1964).

Table II Duration of response (months)

| Response | Number | Duration |
|----------|--------|----------|
| CR (7%)  | 17      | 36, 36, 36 +, 37, 38, 48 +, 52 + (median 37 +) |
| PR (24%) | 7, 7 +  | 8, 8 +, 9, 9, 11, 14 +, 14, 14, 15 +, 16 +, 16, 18, 18 +, 22 +, 36 (median 14 +) |
| SD (15%) | 6, 7, 8, 9, 10 +, 10, 16 +, 18, 37, 45 +, (median 10 +) |
| PD (3%)  | 39 (52%)|          |

Table III Response to goserelin versus ER status of the primary tumour

| No. of patients | ER pos. | ER neg. | Unknown |
|-----------------|---------|---------|---------|
| Complete response | 6       | 1       | -       |
| Partial response | 13      | 2       | 3       |
| Static disease  | 5       | 4       | 2       |
| Progressive disease | 8      | 21      | 10      |

χ² = 20.59, 6 d.f., P < 0.005.

Administration of the LH-RH agonist goserelin to premenopausal advanced breast cancer patients produces a rapid desensitisation of the pituitary gland to endogenous LH-RH, with resultant falls in the circulating levels of LH and FSH (Nicholson et al., 1984, 1985; Williams et al., 1986; Walker et al., 1986). Castrate levels of oestradiol and progesterone are produced within 3–4 weeks although a small group of patients will show recurrent suppressed peaks of oestradiol (Williams et al., 1986). This ability to reduce serum oestradiol is not influenced by either the patient’s age or weight (Nicholson & Walker, 1989). A theoretical limiting factor to treatment with LH-RH agonists, as with radiation castration, is their inability to immediately suppress ovarian activity; surgical oophorectomy produces castrate levels of oestradiol within 2 to 7 days (Vermeulen, 1976; Beksc et al., 1983).

Despite these theoretical shortcomings we reported a response to goserelin of 31% in a phase I study of 53 premenopausal patients (Williams et al., 1986), a value that is comparable to our previous experiences using surgical oophorectomy (Buchanan et al., 1986). When we examined the results of 23 assessable patients who had received a combination of goserelin and the anti-oestrogen tamoxifen we reported a 22% response, with a further 22% of patients showing static disease (Robertson et al., 1989a).

It is apparent from this study of 75 patients that LH-RH agonists are capable of achieving a significant objective response of worthwhile duration in premenopausal advanced breast cancer patients. We report an objective response rate of 33%, with a median duration of response of 15 months (range 7–52). Seven patients (9%) were classified as having had a complete response, the median duration of which was in excess of 37 months. A further 11 patients (15%) had stable disease of at least 6 months duration (median duration 10 months). This group of patients have a similar survival to those that show responsive disease to at 6 months; this concords to our findings in patients treated with megestrol (Robertson et al., 1989b). The remaining 39 patients (52%) had disease progression within 6 months of starting treatment.

It would appear that the presence of the oestrogen receptor in the primary tumour may be predictive of a response to medical oophorectomy using goserelin. This is in accordance to our previous findings (Williams et al., 1986).

Goserelin is easily administered and produces an effective but reversible castration. Objective remissions of worthwhile duration are seen in a third of patients, comparable to surgical oophorectomy but without its potential and irreversible morbidity, psychological traumas and surgical risks. This is particularly important in that 50% of patients will show no response to the ovarian suppression. Monthly administration also ensures a high patient compliance.
References

BEATSON, G.T. (1896). On the treatment of inoperable cases of carcinoma of the mamma; suggestions for a new method of treatment with illustrative cases. *Lancet*, ii, 104.

BEKSAC, M.S., KISNISCI, H.A., CAKAR, A.N. & BEKSAC, M. (1983). The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women. *Int. J. Fertil.*, 28, 219.

BRITISH BREAST GROUP (1974). Assessment of response to treatment in advanced breast cancer. *Lancet*, ii, 38.

BUCHANAN, R.B., BLAMEY, R.W., DURRANT, K.R. & 6 others (1986). A randomised comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. *J. Clin. Oncol.*, 4, 1326.

HAYWARD, J.L., CARBONE, P.P., HEUSON, J.C., KUMAOKA, S., SEGALOF, A. & RUBENS, R.D. (1977). Assessment of response to therapy in advanced breast cancer. A project of the International Union Against Cancer, Geneva, Switzerland. *Cancer*, 39, 1289.

KENNEDY, B.J., MIELKE, P.W. & FORTUNY, I.E. (1964). Therapeutic castration verses prophylactic castration in breast cancer. *Surg. Gynecol. Obstet.*, 118, 524.

LEE, E.T. & DESU, M.M. (1972). A computer program for comparing k samples with right censored data. *Comp. Prog. Biomed.*, 2, 315.

NICHOLSON, R., CAMPBELL, F.C., BLAMEY, R.W., ELSTON, C.W., GEORGE, D. & GRIFFITHS, K. (1981). Steroid receptors in early breast cancer: value in prognosis. *J. Steroid Biochem.*, 15, 193.

NICHOLSON, R.I., WALKER, K.J., TURKES, A. & 6 others (1984). Therapeutic significance and the mechanisms of action of the LH-RH agonist ICI 118630 in breast and prostatic cancer. *J. Steroid Biochem.*, 20, 129.

NICHOLSON, R.I., WALKER, K.J., TURKES, A. & 4 others (1985). Endocrinological and clinical aspects of LH-RH action (ICI 118630) in hormone dependent breast cancer. *J. Steroid Biochem.*, 23, 843.

NICHOLSON, R.I. & WALKER, K.J. (1989). Use of LH-RH agonists in the treatment of breast disease. *Proc. R. Soc. Edin. B.*, 95, 271.

ROBERTSON, J.F.R., WALKER, K.J., NICHOLSON, R.I. & BLAMEY, R.W. (1989a). The combined endocrine effects of LH-RH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. *Br. J. Surg.*, 76, 1262.

ROBERTSON, J.F.R., WILLIAMS, M.R., TODD, J., NICHOLSON, R.I., MORGAN, D.A.L. & BLAMEY, R.W. (1989b). Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. *Eur. J. Clin. Oncol.*, 25, 469.

SPSS (1986). *SPSS User’s Guide*. McGraw-Hill: New York.

VERMEULEN, A. (1976). The hormonal activity of the post menopausal ovary. *J. Clin. Endocrinol. Metab.*, 42, 247.

WALKER, K.J., TURKES, A., WILLIAMS, M.R., BLAMEY, R.W. & NICHOLSON, R.I. (1986). Preliminary endocrinological evaluation of a sustained release formulation of the LH-releasing hormone agonist d-Ser(Bu)6 Axgly(10) LH-RH in premenopausal women with advanced breast cancer. *J. Endocrinol.*, 111, 349.

WALKER, K.J., WALKER, R.F., TURKES, A. & 4 others (1989). Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. *Eur. J. Cancer Clin. Oncol.*, 25, 651.

WILLIAMS, M.R., WALKER, K.J., TURKES, A., BLAMEY, R.W. & NICHOLSON, R.I. (1986). The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. *Br. J. Cancer*, 53, 629.